Claes-Göran Löfdahl

TL;DR: In patients who have persistent symptoms of asthma despite treatment with inhaled glucocorticoids, the addition of formoterol to budesonid therapy or the use of a higher dose of budesonide may be beneficial.

TL;DR: A double-blind, placebo-controlled study evaluated the effect of the inhaled glucocorticoid budesonide in subjects with mild COPD who continued smoking and found that the FEV1 improved at the rate of 17 ml per year in the budesonid group, which was higher than the predicted value.

TL;DR: A Task Force supported by the European Respiratory Society was set up in 1997 in order to address the major issues relevant to difficult/therapy-resistant asthma as mentioned in this paper, and the Task Force also concerned itself with defining the areas of research necessary to bring about a greater understanding of the causes of difficult asthma and novel treatments.

TL;DR: Exacerbations identified by the need for oral corticosteroids were associated with more symptoms and smaller changes in PEF than those identified on the basis of PEF criteria, and female sex was the main patient characteristic associated with an increased risk of having a severe exacerbation.

TL;DR: The results show that HRQL in COPD deteriorates with disease severity and with age, and a relationship between HRQL and disease severity obtained by lung function is shown.